ATG4D and osteosarcoma: Silencing ATG4D led to a significant increase in caspase‐3/7 activity, which was attenuated by a pan‐caspase inhibitor (Figure 1G–I), indicating that ATG4D depletion induces caspase‐3/7‐mediated death in osteosarcoma cells.